The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data-Reference-Cited by-同舟云学术

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data

Published:2023-08-11 Issue: Volume:13 Page:
ISSN:2047-2978
Container-title:Journal of Global Health
language:
Short-container-title:J Glob Health

Author:

Yang Yu¹,Zhang Yichen¹,Wagner Anita K²,Li Huangqianyu³,Shi Luwen¹³,Guan Xiaodong¹³

Affiliation:

1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

2. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA

3. International Research Center for Medicinal Administration, Peking University, Beijing, China

Publisher

International Society of Global Health

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference45 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.;Sung;CA Cancer J Clin,2021

2. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology.;Ozols;J Clin Oncol,2007

3. Targeted cancer therapy.;Sawyers;Nature,2004

4. The Effect of Advances in Lung-Cancer Treatment on Population Mortality.;Howlader;N Engl J Med,2020

5. Enhancing global access to cancer medicines.;Cortes;CA Cancer J Clin,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Factors Influencing Hospitalization Expenses of Patients with Gastric Cancer in Shanghai, 2014-2021: Based on Grey Relational Analysis and Structural Equation Modeling;Value in Health Regional Issues;2024-11

2. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study;The Lancet Regional Health - Western Pacific;2024-09

3. Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation;Therapeutic Advances in Gastroenterology;2024-01